Evidence map›Paper›PMID 41331784›Full record

SynthesisItalian journal of pediatrics2025

Comparison of safety and immunogenicity between Healive®, Havrix® and live attenuated Hepatitis A vaccines in pediatric population: a systematic review with meta-analysis.

Mohamed Abo Zeid, Amr Elrosasy, Mohamad Ali Farho, Mohamed Rifai, Menna M Aboelkhier, Mohamed Nabil Elkhrashy, Ahmed Hamdy Zabady, Mohamed Samir A Zaki, Eman Mostafa Hamed, Samy A Dawood and 1 more

Abstract readSystematic ReviewMeta-AnalysisComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Italian journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohamed Abo ZeidFaculty of Medicine Tanta University, Tanta, Egypt.
Amr ElrosasyFaculty of Medicine, Cairo University, Cairo, Egypt.
Mohamad Ali FarhoFaculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic.ORCID http://orcid.org/0000-0002-3277-2270
Mohamed RifaiFaculty of Medicine Menofyia University, Shebin El Kom, Egypt.ORCID http://orcid.org/0009-0007-9457-9832
Menna M AboelkhierMaster Program, Faculty of Science, Cairo University, Cairo, Egypt.ORCID http://orcid.org/0000-0002-7648-2224
Mohamed Nabil ElkhrashyFaculty of Medicine, Al-Azhar University, Cairo, Egypt.
Ahmed Hamdy ZabadyDepartment of Microbiology, Faculty of Science, Damanhour University, Damanhour, Egypt.
Mohamed Samir A ZakiDepartment of Anatomy, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Eman Mostafa HamedDepartment of Clinical Pharmacy, Faculty of Pharmacy, Galala University, Suez, Egypt.
Samy A DawoodDepartment of Child Health, College of Medicine, King Khalid University, Abha, Saudi Arabia.
Yasmine AbuzaidFaculty of Medicine Tanta University, Tanta, Egypt. yasmine.Abuzaid@med.tanta.edu.eg.ORCID http://orcid.org/0000-0002-2894-7875

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHealive is an inactivated vaccine for hepatitis A virus developed in China and was found to be well-tolerated and highly immunogenic in adults and children. It is our aim this study to compare the safety and immunogenicity of Healive® with Havrix® and live attenuated vaccines in pediatric populations.

methodsA systematic search of PubMed, Scopus, Web of Science, and Embase databases was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing Healive with other vaccines were included.

resultsSeven RCTs involving 3664 patients were included. Healive showed comparable efficacy to Havrix regarding seroconversion rates and GMT at one month (SMD = 0.24, 95% CI [-0.11 to 0.59]), but achieved better results at six (SMD = 0.85, 95% CI [0.57 to 1.07]) and seven months (SMD = 0.55, 95% CI [0.41 to 0.70]). When compared to live attenuated vaccines, Healive demonstrated superior GMT at one month (SMD = 0.31, 95% CI [0.07 to 0.56]) and two years (SMD = 0.36, 95% CI [0.06 to 0.67]).

conclusionHealive appears to be effective and safe for preventing hepatitis A, providing at least five years of protection. This review underscores the importance of ongoing research to optimize hepatitis A vaccination strategies, including standardized assays for antigen content, clarification of protective antibody levels, and large-scale trials in regions of intermediate endemicity.

Indexed as

Hepatitis AHepatitis A VaccinesImmunogenicity, VaccineChildHumansRandomized Controlled Trials as TopicVaccines, AttenuatedVaccines, InactivatedHepatitis A VaccinesVaccines, AttenuatedVaccines, InactivatedHavrixHealive vaccineHepatitis AInactivated vaccineLive attenuated vaccine

Identifiers

PMID41331784
PMCPMC12690888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.